Is checking for off-target edits enough to establish genome-editing safety?

Understanding the question

No. Off-target editing is only one part of the safety assessment. Editing can also produce unintended changes at the intended genomic location, including larger rearrangements or changes that a narrowly focused assay misses. Researchers must consider the delivery system, the proportion and identity of edited cells, functional consequences, immune effects, and how altered cells behave over time. A negative off-target screen means no relevant changes were detected under that method and its sensitivity, not that every cell is genetically unchanged outside the intended edit. Safety conclusions require complementary measurements and appropriate biological follow-up.

What a useful investigation needs to consider

Different editing technologies create different types of changes. A safety assessment designed for one platform cannot simply be transferred to another without considering its mechanism, delivery, and potential byproducts.

Sampling matters because rare changes can be diluted within a mixed cell population. The tissues tested, the number of cells represented, and the sensitivity of sequencing or other assays determine what a negative result can exclude.

Correcting a sequence and improving a clinically important function are separate outcomes. Even a precisely measured edit must be assessed for effects on cell behavior, tissue performance, and long-term risk in the intended population.

Read the detailed explanation

The companion article explores off-target and unintended on-target changes in genome editing in more depth, with topic-specific explanations and source material.